New drug for fatty liver disease takes first step in human trials
NCT ID NCT06705998
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This early-stage study tests the safety of a new drug called BAR502 in 52 healthy adults aged 18-55. The drug is being developed for NASH, a serious liver condition. Participants receive either the drug or a placebo to check for side effects and how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CROSS Research S.A. Phase I Unit
RECRUITINGArzo, CH-6864, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.